Hing C. Wong, Chief Executive Officer, 10% Owner at HCW Biologics Inc. (HCWB), bought 113,879 shares at $1.41 ($160K) on 2026-05-22, disclosed to the SEC on 2026-05-27.
HCW Biologics CEO Hing C. Wong purchased 113,879 shares for $160,000, marking the largest insider purchase in the company's history. This significant buy comes as the stock has surged over 350% in the last 30 days, suggesting the CEO sees further upside despite the recent pullback.
The stock has experienced extreme volatility, rallying 354.65% over the last 30 days before dropping 19.42% in the past five days. It remains deeply undervalued, trading at a 77.7% discount to its 52-week high of $8.75.
Insider buying momentum: The trade is flagged as the 'largest ever' insider purchase, signaling strong conviction from the CEO. Sector rotation: Recent news highlights a rotation into micro-cap turnarounds with operational catalysts, positioning HCW Biologics as a beneficiary of this market trend.
High volatility: The stock's beta of 2.36 indicates it is significantly more volatile than the broader market. Short interest: While low at 1.4%, the stock's massive run-up of 354.65% in 30 days increases the risk of a sharp correction.
Nothing distinguishes this filing.
| Filing → |
| HCWB | BUY | 2025-05-09 | $2.4M | — | Filing → |
| HCWB | BUY | 2023-09-18 | $4K | — | Filing → |
| HCWB | BUY | 2023-06-02 | $3K | — | Filing → |